KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Short term Debt (2016 - 2025)

Historic Short term Debt for Amgen (AMGN) over the last 14 years, with Q4 2025 value amounting to $4.6 billion.

  • Amgen's Short term Debt rose 2954.93% to $4.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.6 billion, marking a year-over-year increase of 2954.93%. This contributed to the annual value of $4.6 billion for FY2025, which is 2954.93% up from last year.
  • Latest data reveals that Amgen reported Short term Debt of $4.6 billion as of Q4 2025, which was up 2954.93% from $2.2 billion recorded in Q3 2025.
  • Amgen's 5-year Short term Debt high stood at $5.5 billion for Q2 2024, and its period low was $87.0 million during Q4 2021.
  • Its 5-year average for Short term Debt is $2.5 billion, with a median of $2.2 billion in 2023.
  • Per our database at Business Quant, Amgen's Short term Debt skyrocketed by 465164.84% in 2021 and then crashed by 8110.55% in 2022.
  • Over the past 5 years, Amgen's Short term Debt (Quarter) stood at $87.0 million in 2021, then surged by 1728.74% to $1.6 billion in 2022, then dropped by 9.3% to $1.4 billion in 2023, then surged by 146.02% to $3.6 billion in 2024, then increased by 29.55% to $4.6 billion in 2025.
  • Its Short term Debt was $4.6 billion in Q4 2025, compared to $2.2 billion in Q3 2025 and $2.4 billion in Q2 2025.